479 related articles for article (PubMed ID: 26567276)
1. Development of New Strategies for Echinocandins: Progress in Translational Research.
Walsh TJ; Azie N; Andes DR
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
[TBL] [Abstract][Full Text] [Related]
2. The Role of Echinocandins in Candida Biofilm-Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems.
Ghannoum M; Roilides E; Katragkou A; Petraitis V; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S618-21. PubMed ID: 26567279
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
4. [Could antifungal lock be useful in the management of candidiasis linked with catheters?].
Cateau E; Rodier MH; Imbert C
Med Sci (Paris); 2012; 28(8-9):740-5. PubMed ID: 22920876
[TBL] [Abstract][Full Text] [Related]
5. Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces.
Katragkou A; Roilides E; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S622-9. PubMed ID: 26567280
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
7. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
Glöckner A
Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
9. [Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins].
Almirante B; Garnacho-Montero J; Maseda E; Candel FJ; Grau S; Guinea J; Moreno I; Muñoz P; Ruiz-Santana S
Rev Esp Quimioter; 2017 Oct; 30(5):355-367. PubMed ID: 28945064
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.
Kale-Pradhan PB; Morgan G; Wilhelm SM; Johnson LB
Pharmacotherapy; 2010 Dec; 30(12):1207-13. PubMed ID: 21114387
[TBL] [Abstract][Full Text] [Related]
11. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
12. Echinocandins: The Expanding Antifungal Armamentarium.
Aguilar-Zapata D; Petraitiene R; Petraitis V
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S604-11. PubMed ID: 26567277
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.
Mariné M; Pastor FJ; Sahand IH; Pontón J; Quindós G; Guarro J
Antimicrob Agents Chemother; 2009 Dec; 53(12):5297-9. PubMed ID: 19786599
[TBL] [Abstract][Full Text] [Related]
15. Austrian clinical practice with anidulafungin in 2008: a multicenter survey.
Perkhofer S; Hell M; Gustorff B; Von Goedecke A; Illievich U; Kratzer C; Moosbauer W; Wimmer P; Zerlauth U; Nachbaur K; Vogel W; Bellmann R; Schwameis F; Lass-Flörl C
J Chemother; 2011 Oct; 23(5):285-9. PubMed ID: 22005061
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
Kofla G; Ruhnke M
Eur J Med Res; 2011 Apr; 16(4):159-66. PubMed ID: 21486730
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
18. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
Xu G; Zhu L; Liao S; Ge T; Yang J
Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
[TBL] [Abstract][Full Text] [Related]
19. New developments and directions in the clinical application of the echinocandins.
Chang CC; Slavin MA; Chen SC
Arch Toxicol; 2017 Apr; 91(4):1613-1621. PubMed ID: 28180946
[TBL] [Abstract][Full Text] [Related]
20. Lack of efficacy of echinocandins against high metabolic activity biofilms of Candida parapsilosis clinical isolates.
Thomaz DY; Melhem MSC; de Almeida Júnior JN; Benard G; Del Negro GMB
Braz J Microbiol; 2020 Sep; 51(3):1129-1133. PubMed ID: 31898245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
